US Stocks Movement | ARS Pharmaceuticals plummets 21% pre-market as it fails to secure new payer coverage and lowers full-year expense guidance
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Don't Be Misled by "Instant Purchase, Instant Access": Pro Series Zero Wait Has Been the Norm for Years, UBS Maintains Apple (AAPL.US) Target Price at $340
The waiting time for iPhone 18 Pro is approaching zero, and Duo deliveries are scheduled until the end of January. UBS maintains its forecast for iPhone revenue in the December quarter at $95.1 billions, representing a year-on-year increase of 11.5%.
Nvidia's "black swan" shakes up AI faith! Jensen Huang's controversy draws in U.S. Treasury bond buying, long-term U.S. Treasuries rise against the trend
After a brief holiday break, the US Treasury market has resumed trading, with long-term US Treasury prices rising slightly. The recent turmoil surrounding Nvidia has caused doubts about the main AI trading narrative, prompting safe-haven buying into US Treasuries.
BoJ's Asada says must be mindful of expected effect of past rate increases on economy
Crypto prices
More
